Sedia receives NIAID grant for Phase II research of HIV assay
Sedia received a Notice of Award from the NIAID, a subsidiary of the National Institutes of Health, granting Phase II funding for the research of its HIV-1 Limiting Antigen-Avidity EIA single well enzyme assay under a Small Business Innovation Research grant. The assay utilizes licensed technology from the U.S. Centers of Disease Control and Prevention to measure the maturity of HIV antibodies and the progression of HIV infection in a host.
The assay is currently on the market as a Research Use Only product to measure the incidence of HIV and spread of infection, and is used by the CDC Ministries of Public Health and other public health groups worldwide. The completion of a Phase II trial will enable Sedia to potentially gain FDA approval for diagnostic use.
"Sedia has been very pleased with the reception that the Sedia HIV-1 LAg-Avidity EIA has received in the public health community and we are excited about the possibility of providing this as an aid to characterizing individual infections to better combat the HIV epidemic" Sedia President and Chief Science Officer Dr. Ronald Mink said. "The ongoing support for this assay from CDC NIH and a broad range of public health groups around the world we believe demonstrates the value of making this assay available to clinicians treating infected individuals enabling them to better understand the disease state in such individuals."